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Background: Platinum-based chemotherapy (CT) for previously 
untreated advanced NSCLC improves survival (OS) and QoL but can 
have considerable toxicity. Erlotinib (E) (Tarceva®), an oral EGFR 
inhibitor, improves OS and progression-free survival (PFS) in 2nd- and 
3rd-line treatment of NSCLC with acceptable toxicity, similar response 
and OS to chemotherapy, and a suggestion that pts whose tumors 
express EGFR might beneﬁt most. In unselected CT-naïve NSCLC pts, 
adding daily E to concurrent CT did not improve outcome. Preclinical 
data suggest that intercalating E with CT may be superior to continu-
ous concurrent dosing. This trial was designed to evaluate E alone or 
E intercalated with CT for front-line treatment in an EGFR-selected 
population.
Methods: CT-naïve stage IIIB/IV NSCLC pts, ECOG PS 0-2, with 
EGFR-positive tumors by FISH or IHC were randomized equally to E 
150 mg/d or carboplatin AUC 6/paclitaxel 200 mg/m2 on Day 1 plus E 
150 mg/d on Days 2-15 of every 21-day cycle (ECP). After 4 cycles, pts 
in both arms continued daily E until PD, refusal, unacceptable toxicity, 
or death. EGFR IHC and FISH testing are performed at the University 
of Colorado Cancer Center with a planned 5-day or less turnaround. 
Stratiﬁcation factors are: number of positive (1 vs. 2) EGFR tests, 
performance status (0/1 vs. 2), extent of disease (stage IIIB vs. IV), and 
cigarette smoking status (current vs. former vs. never). The primary 
study endpoint is disease progression at 6 months. Secondary endpoints 
include PFS, OS, and response rate. Enrollment goal is 140 pts.
Results: As of February 19, 2007, 66 pts have been randomized (33 E; 
33 ECP). Median age is 61 yrs (range, 31-87); 61% are female; 12% 
Asian; 36% never smokers, 12% current smokers, and 52% former 
smokers; 94% ECOG PS 0/1; 89% Stage IV; 77% adenocarcinoma. 
Median EGFR reporting time is 4 days (range, 1-9). 88% of random-
ized pts’ tumors are IHC positive, 53% FISH positive, and 41% 
are both IHC and FISH positive for EGFR. 123 patients have been 
screened: 8% of pts’ tumors are EGFR IHC and FISH negative and 
15% are not sufﬁcient for EGFR testing. Of randomized patients, 12% 
have EGFR mutations and 11% have KRAS mutations. There are no 
notable differences in demographics or baseline characteristics between 
arms with the exception of more females and PS 0 patients in the E 
arm. Preliminary safety data show no notable differences between treat-
ment arms.
Conclusions: Selection of untreated advanced NSCLC pts for E 
therapy based on real-time EGFR testing of tumor tissue is feasible. 
Preliminary evaluation of efﬁcacy and safety data will be presented.
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Background: Erlotinib (Tarceva®), a potent, orally active inhibitor of 
EGFR tyrosine kinase, signiﬁcantly prolonged survival, delayed symp-
tom progression and improved quality of life compared with placebo in 
patients with relapsed NSCLC (Shepherd et al. NEJM 2005;353:123-
132). Exploratory univariate analyses suggested a beneﬁcial effect of 
erlotinib on survival in patients with EGFR-positive tumours or high 
EGFR gene copy number (Tsao et al. NEJM;353:133-144). In a mul-
tivariate analysis, survival on erlotinib was not signiﬁcantly affected 
by EGFR expression status, EGFR copy number, or EGFR mutation 
status, but relationships between such markers and clinical outcomes on 
erlotinib have not been prospectively evaluated. The goal of the multi-
centre, open-label phase II MERIT study was to identify molecular 
markers that may be predictive for clinical beneﬁt with erlotinib. 
Methods: Eligible patients had advanced (stage IIIB/IV) NSCLC, 
ECOG PS 0-2, were ≥ 18 years old, and had failed ≥ one chemotherapy 
regimen (or refused/were unsuitable for chemotherapy). An important 
inclusion criterion was that a tumour biopsy should be performed by 
bronchoscopy prior to the start of treatment. Erlotinib (150mg/day p.o.) 
was given until disease progression, death, or unacceptable toxicity. 
Dose reductions were permitted for adverse events (AEs). Tumour re-
sponse was assessed every 6 weeks until week 24, then every 12 weeks. 
Clinical beneﬁt was deﬁned as either an objective response (RECIST), 
or stable disease ≥ 12 weeks. Safety assessments (laboratory tests and 
AE recording) were performed at regular intervals. Tumour biopsies 
were analysed using gene expression proﬁling on fresh-frozen tissue, 
and IHC for EGFR and downstream signalling molecules. Receptor 
mutations were evaluated by DNA sequencing, and gene ampliﬁcation 
was assessed using FISH. 
Results: 264 patients from 26 centres in 12 countries were available 
for evaluation of efﬁcacy. Their median age was 61.0 years (range 
32–85). Other baseline characteristics were: male, 70%; female 30%; 
stage IIIB, 26%; stage IV, 74%; ECOG PS 0, 13%; PS 1, 64%; PS 2, 
23%; Caucasian, 61%; Oriental, 38%; other, <1%; non-smoker, 27%; 
ever-smoker, 73% (current, 27%; past, 46%); adenocarcinoma, 41%; 
squamous-cell carcinoma, 38%; large-cell carcinoma, 5%; other, 17%. 
236 patients (89.4%) had previously received chemotherapy (includ-
ing neo-adjuvant and adjuvant treatment). For most patients in MERIT 
(130; 49.2%) erlotinib was second-line therapy, but 72 (27.3%) re-
ceived third-line and 62 (23.5%) ﬁrst-line erlotinib. 36 patients (13.6%) 
had an objective response; 83 (31.4%) had clinical beneﬁt. Median 
overall survival was 7.6 months (95% CI 7-9); median progression-free 
survival was 11.3 weeks (95% CI 8-12). 226 of 257 patients (87.9%) 
had at least one AE, and 62 (24.1%) had a serious AE. 193 patients 
(75.1%) had at least one treatment-related AE and 37.4% had at least 
one AE ≥ grade (gr) 3. The most common AEs were: rash (61.9%; 
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9.3% ≥ gr 3); diarrhoea (30.7%; 2.7% ≥ gr 3), dyspnoea (16.7%; 6.2% 
≥ gr 3) and anorexia (16%; 0.8% ≥ gr 3). Treatment discontinuation due 
to AEs occurred in 5.8% of patients, and 12% had dose reductions. 
Conclusions: MERIT is the largest ever prospective biomarker trial 
conducted in NSCLC. The results support the use of erlotinib (Tarce-
va®) as an effective and well tolerated alternative to chemotherapy for 
patients with advanced NSCLC who have failed at least one previous 
chemotherapy regimen. Data on the relationships between molecular 
markers and obtaining clinical beneﬁt with erlotinib will be presented.
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Background: Epidermal growth factor receptor (EGFR) gene copy 
number by ﬂuorescence in-situ hybridization (FISH) is a predictor of 
survival beneﬁt from EGFR inhibitor monotherapy, as demonstrated in 
prospective placebo-controlled clinical trials in advanced NSCLC. We 
aimed to investigate the predictive role of EGFR gene copy number in 
patients treated in a clinical study testing the combination of erlotinib 
and chemotherapy (TRIBUTE trial).
Methods: TRIBUTE was a phase III clinical trial that randomly as-
signed 1.059 patients to carboplatin and paclitaxel (CP) with erlotinib/
placebo followed by maintenance erlotinib/placebo. There was no dif-
ference in overall survival or progression-free survival between treat-
ment groups (P=0.95 and P=0.36, respectively). We analyzed 275 tissue 
samples from study participants (26% of study population) for EGFR 
gene copy number by FISH using commercially available EGFR/CEP7 
probe (Abbott Molecular, Des Plaines, IL, USA) and previously estab-
lished scoring criteria (Cappuzzo et al., 2005). 
Results: The results of EGFR FISH test were available for 245 
patients (89% of group subjected to analysis, including 121 patients 
who received erlotinib and 124 who received placebo). In this group 
of patients, time-to-progression (TTP) was not different between 
study arms but overall survival (OS) was longer for placebo than for 
erlotinib (median 13.2 months vs. 9.6 months, respectively, P=0.033). 
One hundred patients were EGFR FISH positive (FISH+, 40.8%). In 
the FISH+ subset, objective response rates to CP and erlotinib vs. CP 
and placebo were 11.6% and 29.8%, respectively (P=0.049). Response 
rates in FISH- subset of patients were 21.8% vs. 25.4%, respectively 
(P=0.695). In FISH+ patients, TTP was signiﬁcantly longer for 
erlotinib vs. placebo (HR=0.59, 95%CI: 0.35-0.99 log-rank P=0.043) 
and the difference was observed mainly after six months of treatment. 
There was no difference in OS (HR=1.52, 95% CI: 0.94-2.46, log-rank 
P=0.083). In FISH- patients, TTP and OS were not different between 
treatment arms (HR=1.42, 95%CI: 0.95-2.14, log-rank P=0.089 and 
HR=1.24, 95%CI: 0.84-1.82, log-rank P=0.278, respectively). The 
treatment by EGFR FISH interaction test was signiﬁcant for TTP 
(P=0.007) but not for OS (P=0.49).
Conclusion: EGFR gene copy number assessment by FISH may 
predict longer TTP in advanced NSCLC patients treated with ﬁrst-
line chemotherapy and erlotinib. This difference is seen mainly after 
completion of chemotherapy. The predictive value of EGFR FISH test 
on OS was not conﬁrmed. These exploratory results suggest the beneﬁt 
from maintenance erlotinib after completion of chemotherapy in FISH+ 
group of patients.
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Background: The role of speciﬁc EGFR genotypes and the efﬁcacy of 
treatment with geﬁtinib or erlotinib shows that patients with somatic 
exon 19 deletions are associated with longer time to progression and 
overall survival than patients with exon 21 point mutations. For other 
mutations in EGFR and KRAS, their speciﬁc role in sensitivity or 
resistance to treatment with an EGFR-TKI is less well described. In 
light of the relative infrequency of some of these mutations, we have 
created a mutation registry to track protocol-based clinical outcomes 
with speciﬁc mutations in previously untreated patients with NSCLC 
treated with erlotinib and geﬁtinb. By including only chemotherapy-
naïve patients, we are better able to judge the impact of EGFR-TKI 
therapy in tumors that have not been exposed to the effects of cytotoxic 
chemotherapeutic agents.
Methods: A web-based database has been created to compile the 
results of trials of EGFR-TKI therapy in chemotherapy-naïve patients. 
To date, three clinical trials have been included in this registry. In all 3 
trials, chemotherapy-naïve patients with Stage IIIB and IV NSCLC and 
PS 0-2 were treated with erlotinib 150 mg/d. One trial of 53 patients 
did not limit enrollment by any clinical or molecular characteristics. A 
second trial was limited to 80 patients age 70 or older. A third trial has 
accrued 49 women with adenocarcinoma who were former or never 
smokers; this trial mandated availability of tissue for EGFR and KRAS 
testing. 
Results: A total of 182 patients have been enrolled in these 3 trials 
from 2003 until the present; 112 patients were successfully screened 
for EGFR mutations, with 105 screened for KRAS. Table 1 includes 
the mutations detected, and the clinical outcomes associated with each 
genotype. The correlation between improved outcome and exon 19 
deletions and L858R mutations is again noted. In addition, the exon 19 
deletions are associated with improved TTP (16.6 vs 9.7 mo, p = .005) 
and OS (23+ vs 14.6 mo, p = .0002) compared with L858R mutations. 
Consistent with earlier literature, the association between resistance 
to erlotinib therapy and KRAS mutations, exon 20 insertions (1 pt, 
survival 1.5 months), and the T790M mutation (1 patient, survival 0.8 
months) is noted. Despite the small sample sizes, we did observe that 
codon 12 mutations of KRAS were associated with longer TTP (3.8 vs. 
1.2 mo, p=0.05) and OS (15.5 vs. 3.3 mo, p = .005) compared with the 
four patients with other KRAS mutations. 
